RAPT Therapeutics Shares up About 7% After H.c. Wainwright Upgrades to 'buy' From 'neutral' on Allergy Drug License Deal
RAPT Therapeutics的股价在H.C. Wainwright将其评级从中立上调至'买入'后上涨约7%,这是因为过敏药物许可交易。
RAPT Therapeutics Shares up About 7% After H.c. Wainwright Upgrades to 'buy' From 'neutral' on Allergy Drug License Deal
RAPT Therapeutics的股价在H.C. Wainwright将其评级从中立上调至'买入'后上涨约7%,这是因为过敏药物许可交易。
使用浏览器的分享功能,分享给你的好友吧